Fulvestrant for advanced male breast cancer patients: A case series

Annals of Oncology

Volumn 22, Issue 4, 2011, Pages 985-

  Masci, G ^a   Gandini, C ^a   Zuradelli, M ^a   Pedrazzoli, P ^a   Torrisi, R ^a   Lutman, F R ^a   Santoro, A ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; FULVESTRANT;

ADVANCED CANCER; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CASE STUDY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PUBLICATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79953296441     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr005     Document Type: Letter

References (5)

1. Korde LA, Zujewski JA, Kamin L et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010; 28: 2114-2122.
2. Johnston SJ, Cheung KL. Fulvestrant-a novel endocrine therapy for breast cancer. Curr Med Chem 2010; 17: 902-914.
3. de la Haba Rodríguez JR, Porras Quintela I, Pulido Cortijo G, Berciano Guerrero M, Aranda E. Fulvestrant in advanced male breast cancer. Ann Oncol 2009; 20: 1986-1987.
4. Agrawal A, Cheung KL, Robertson JF. Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat 2007; 101: 123.
5. Taxel P, Kennedy DG, Fall PM et al. The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. Clin Endocrinol Metab 2001; 86: 2869-2874.